[1] SONG J L, OUYANG Y M, CHE J Y, et al. Potential value of miR-221/222 as diagnostic, prognostic, and therapeutic biomarkers for diseases[J]. Front Immunol, 2017, 8:56. [2] ZHAO J J, LIN J, YANG H, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer[J]. J Biol Chem, 2008, 283(45):31079-31086. [3] KOLB A F, SORRELL D, LASSNIG C, et al. Mammary gland development is delayed in mice deficient for aminopeptidase N[J]. Transgenic Res, 2013, 22(2):425-434. [4] DAVIS D G, SIDDIQUI M T, OPREA-ILIES G, et al. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas[J]. Hum Pathol, 2016, 47(1):26-31. [5] GIULIANO A E, EDGE S B, HORTOBAGYI G N. Eighth edition of the AJCC cancer staging manual:breast cancer[J]. Ann Surg Oncol, 2018, 25(7):1783-1785. [6] BANET N, GOWN A M, SHIH IEM, et al. GATA-3 expression in trophoblastic tissues:an immunohistochemical study of 445 cases, including diagnostic utility[J]. Am J Surg Pathol, 2015, 39(1):101-108. [7] HISAMATSU Y, TOKUNAGA E, YAMASHITA N, et al. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer[J]. Breast Cancer, 2015, 22(5):520-528. [8] LI F, WANG F, ZHU C, et al. miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker[J]. Int J Nanomedicine, 2018, 13:2295-2307. [9] LI F, XU J W, WANG L, et al. microRNA-221-3p is up-regulated and serves as a potential biomarker in pancreatic cancer[J]. Artif Cells Nanomed Biotechnol, 2018, 46(3):482-487. [10] AMBROZKIEWICZ F, KARCZMARSKI J, KULECKA M, et al. Challenges in cancer biomarker discovery exemplified by the identification of diagnostic microRNAs in prostate tissues[J]. Biomed Res Int, 2020, 2020:9086829. [11] AMINI S, ABAK A, ESTIAR M A, et al. Expression analysis of MicroRNA-222 in breast cancer[J]. Clin Lab, 2018, 64(4):491-496. [12] CHERNYY V, PUSTYLNYAK V, KOZLOV V, et al. Increased expression of miR-155 and miR-222 is associated with lymph node positive status[J]. J Cancer, 2018, 9(1):135-140. [13] IIDA M, HAZAMA S, TSUNEDOMI R, et al. Overexpression of miR-221 and miR-222 in the cancer stroma is associated with malignant potential in colorectal cancer[J]. Oncol Rep, 2018, 40(3):1621-1631. [14] SONG Y, HE M, ZHANG J, et al. High expression of microRNA 221 is a poor predictor for glioma[J]. Medicine:Baltimore, 2020, 99(49):e23163. [15] CAKIR A, ISIK GONUL I, EKINCI O, et al. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas[J]. Pathol Res Pract, 2017, 213(3):227-234. [16] ASSELIN-LABAT M L, SUTHERLAND K D, BARKER H, et al. GATA-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation[J]. Nat Cell Biol, 2007, 9(2):201-209. [17] YILDIRIM E, BEKTAS S, GUNDOGAR O, et al. The relationship of GATA3 and ki-67 with histopathological prognostic parameters, locoregional recurrence and disease-free survival in invasive ductal carcinoma of the breast[J]. Anticancer Res, 2020, 40(10):5649-5657. [18] HORIMOTO Y, SASAHARA N, SASAKI R, et al. High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer[J]. Breast Cancer Res Treat, 2020, 183(1):41-48. [19] RAO X, DI LEVA G, LI M, et al. microRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways[J]. Oncogene, 2011, 30(9):1082-1097. [20] ZHAO J J, LIN J, YANG H, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer[J]. J Biol Chem, 2008, 283(45):31079-31086. [21] GAN R, YANG Y, YANG X, et al. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3[J]. Cancer Gene Ther, 2014, 21(7):290-296. [22] LI Y, LIANG C L, MA H Z, et al. miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer[J]. Mol Basel Switz, 2014, 19(6):7122-7137. [23] LI B, LU Y, WANG H, et al. miR-221/222 enhance the tumorigenicity of human breast cancer stem cells via modulation of PTEN/Akt pathway[J]. Biomed Pharmacother, 2016, 79:93-101. [24] MILLER T E, GHOSHAL K, RAMASWAMY B, et al. microRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1[J]. J Biol Chem, 2008, 283(44):29897-29903. |